Last reviewed 2026-04-22 · How we verify

DAPA/MET XR

Woman's · Phase 3 active Small molecule

DAPA/MET XR is a SGLT2 inhibitor + biguanide combination Small molecule drug developed by Woman's. It is currently in Phase 3 development for Type 2 diabetes mellitus. Also known as: Xigduo 5mg/1000 mg.

DAPA/MET XR is a fixed-dose combination of dapagliflozin (SGLT2 inhibitor) and metformin extended-release that lowers blood glucose by increasing urinary glucose excretion and reducing hepatic glucose production.

At a glance

Generic name	DAPA/MET XR
Also known as	Xigduo 5mg/1000 mg
Sponsor	Woman's
Drug class	SGLT2 inhibitor + biguanide combination
Target	SGLT2; metformin (mitochondrial complex I)
Modality	Small molecule
Therapeutic area	Diabetes
Phase	Phase 3

Mechanism of action

Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, promoting glucose excretion in urine independent of insulin secretion. Metformin reduces hepatic glucose production and improves insulin sensitivity. The combination provides complementary mechanisms for glycemic control in type 2 diabetes.

Approved indications

Type 2 diabetes mellitus

Common side effects

Genital mycotic infections
Urinary tract infections
Gastrointestinal disturbances (nausea, diarrhea)
Polyuria
Volume depletion

Key clinical trials

Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DAPA/MET XR CI brief — competitive landscape report
DAPA/MET XR updates RSS · CI watch RSS
Woman's portfolio CI

Frequently asked questions about DAPA/MET XR

What is DAPA/MET XR?

DAPA/MET XR is a SGLT2 inhibitor + biguanide combination drug developed by Woman's, indicated for Type 2 diabetes mellitus.

How does DAPA/MET XR work?

What is DAPA/MET XR used for?

DAPA/MET XR is indicated for Type 2 diabetes mellitus.

Who makes DAPA/MET XR?

DAPA/MET XR is developed by Woman's (see full Woman's pipeline at /company/woman-s).

Is DAPA/MET XR also known as anything else?

DAPA/MET XR is also known as Xigduo 5mg/1000 mg.

What drug class is DAPA/MET XR in?

DAPA/MET XR belongs to the SGLT2 inhibitor + biguanide combination class. See all SGLT2 inhibitor + biguanide combination drugs at /class/sglt2-inhibitor-biguanide-combination.

What development phase is DAPA/MET XR in?

DAPA/MET XR is in Phase 3.

What are the side effects of DAPA/MET XR?

Common side effects of DAPA/MET XR include Genital mycotic infections, Urinary tract infections, Gastrointestinal disturbances (nausea, diarrhea), Polyuria, Volume depletion.

What does DAPA/MET XR target?

DAPA/MET XR targets SGLT2; metformin (mitochondrial complex I) and is a SGLT2 inhibitor + biguanide combination.

Drug class: All SGLT2 inhibitor + biguanide combination drugs
Target: All drugs targeting SGLT2; metformin (mitochondrial complex I)
Manufacturer: Woman's — full pipeline
Therapeutic area: All drugs in Diabetes
Indication: Drugs for Type 2 diabetes mellitus
Also known as: Xigduo 5mg/1000 mg
Compare: DAPA/MET XR vs similar drugs
Pricing: DAPA/MET XR cost, discount & access